New pill aims to ease Parkinson's motor symptoms when added to standard therapy
NCT ID NCT07647614
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether ENERGI-F705 tablets, taken twice daily alongside standard Parkinson's medications, can improve motor function and safety in people aged 40–75 with idiopathic Parkinson's disease. Participants are randomly assigned to receive a high dose, low dose, or placebo for 72 weeks. The study measures side effects and changes in movement using a standard rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ENERGI-F705 tablets
What this could lead to
If successful, this could provide a new add-on treatment option to help control motor symptoms in people with Parkinson's disease.
What could go wrong
This is an early phase 2 trial with only 105 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Neurology, Shuang Ho Hospital
New Taipei City, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Taipei Medical University Hospital
Taipei, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••